In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Contributors will get treatment until finally disorder progression or the participants are unable to tolerate the study drugs. Celastrol was identified to be a Myb inhibitor that suppressed C/EBPβ action and https://lewist099eqa1.tdlwiki.com/user